Noxopharm Ltd (AU:NOX) — Market Cap & Net Worth
Market Cap & Net Worth: Noxopharm Ltd (NOX)
Noxopharm Ltd (AU:NOX) has a market capitalization of $13.26 Million (AU$18.74 Million) as of September 24, 2026. Listed on the AU stock exchange, this Australia-based company holds position #26431 globally and #1202 in its home market, demonstrating a -18.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Noxopharm Ltd's stock price AU$0.06 by its total outstanding shares 307237950 (307.24 Million). Also see balance sheet size of Noxopharm Ltd for a full breakdown of the balance sheet.
Noxopharm Ltd Market Cap History: 2016 to 2026
Noxopharm Ltd's market capitalization history from 2016 to 2026. Data shows change from $91.30 Million to $13.26 Million (-10.38% CAGR). Also see NOX cash flow metrics for how efficiently the company converts equity into cash flow.
Noxopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Noxopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Noxopharm Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.17x
Noxopharm Ltd's market cap is 7.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $91.30 Million | $360.00 | -$704.73K | 253622.16x | N/A |
| 2017 | $245.65 Million | $126.30K | -$3.05 Million | 1945.00x | N/A |
| 2018 | $91.30 Million | $916.53K | -$18.28 Million | 99.62x | N/A |
| 2019 | $60.87 Million | $3.75 Million | -$11.22 Million | 16.23x | N/A |
| 2020 | $106.52 Million | $8.28 Million | -$272.09K | 12.86x | N/A |
| 2021 | $84.78 Million | $5.61 Million | -$9.35 Million | 15.12x | N/A |
| 2022 | $31.52 Million | $5.43 Million | -$18.67 Million | 5.81x | N/A |
| 2023 | $15.43 Million | $6.01 Million | -$15.06 Million | 2.57x | N/A |
| 2024 | $20.22 Million | $2.40 Million | -$3.58 Million | 8.42x | N/A |
| 2025 | $20.22 Million | $2.82 Million | -$4.88 Million | 7.17x | N/A |
Competitor Companies of NOX by Market Capitalization
Companies near Noxopharm Ltd in the global market cap rankings as of September 24, 2026. Review Noxopharm Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Noxopharm Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Noxopharm Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Noxopharm Ltd's market cap moved from $91.30 Million to $ 13.26 Million, with a yearly change of -10.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$13.26 Million | -34.41% |
| 2025 | AU$20.22 Million | 0.00% |
| 2024 | AU$20.22 Million | +30.99% |
| 2023 | AU$15.43 Million | -51.03% |
| 2022 | AU$31.52 Million | -62.82% |
| 2021 | AU$84.78 Million | -20.41% |
| 2020 | AU$106.52 Million | +75.00% |
| 2019 | AU$60.87 Million | -33.33% |
| 2018 | AU$91.30 Million | -62.83% |
| 2017 | AU$245.65 Million | +169.05% |
| 2016 | AU$91.30 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Noxopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.26 Million USD |
| MoneyControl | $13.26 Million USD |
| MarketWatch | $13.26 Million USD |
| marketcap.company | $13.26 Million USD |
| Reuters | $13.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more